- Home
- GRVY vs ALLO Comparison
GRVY vs ALLO Comparison
Compare GRVY & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRVY
- ALLO
- Stock Information
- Founded
- GRVY 2000
- ALLO 2017
- Country
- GRVY South Korea
- ALLO United States
- Employees
- GRVY N/A
- ALLO N/A
- Industry
- GRVY Business Services
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRVY Consumer Discretionary
- ALLO Health Care
- Exchange
- GRVY Nasdaq
- ALLO Nasdaq
- Market Cap
- GRVY 611.8M
- ALLO 545.8M
- IPO Year
- GRVY 2005
- ALLO 2018
- Fundamental
- Price
- GRVY $67.33
- ALLO $2.69
- Analyst Decision
- GRVY
- ALLO Buy
- Analyst Count
- GRVY 0
- ALLO 12
- Target Price
- GRVY N/A
- ALLO $10.26
- AVG Volume (30 Days)
- GRVY 35.3K
- ALLO 1.7M
- Earning Date
- GRVY 11-12-2024
- ALLO 10-31-2024
- Dividend Yield
- GRVY N/A
- ALLO N/A
- EPS Growth
- GRVY N/A
- ALLO N/A
- EPS
- GRVY 9.40
- ALLO N/A
- Revenue
- GRVY $399,940,412.00
- ALLO $65,000.00
- Revenue This Year
- GRVY N/A
- ALLO N/A
- Revenue Next Year
- GRVY N/A
- ALLO $6,292.80
- P/E Ratio
- GRVY $6.38
- ALLO N/A
- Revenue Growth
- GRVY N/A
- ALLO 6.56
- 52 Week Low
- GRVY $57.37
- ALLO $2.01
- 52 Week High
- GRVY $88.85
- ALLO $5.78
- Technical
- Relative Strength Index (RSI)
- GRVY 65.31
- ALLO 49.96
- Support Level
- GRVY $57.37
- ALLO $2.55
- Resistance Level
- GRVY $60.67
- ALLO $2.87
- Average True Range (ATR)
- GRVY 2.26
- ALLO 0.17
- MACD
- GRVY 0.73
- ALLO 0.00
- Stochastic Oscillator
- GRVY 88.53
- ALLO 46.67
About GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.